Research programme: oral therapeutics - Global Blood Therapeutics

Drug Profile

Research programme: oral therapeutics - Global Blood Therapeutics

Alternative Names: GB 18713; GBT 018713; GBT 1118

Latest Information Update: 04 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Global Blood Therapeutics
  • Class Small molecules
  • Mechanism of Action Haemoglobin modulators; Kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hereditary angioedema; Hypoxia

Most Recent Events

  • 13 May 2016 Pharmacodynamics data from a preclinical study presented at the 112th International Conference of the American Thoracic Society
  • 29 Mar 2016 Global Blood Therapeutics intends to file an IND application with the US FDA in USA for Hereditary angioedema (Global Blood Therapeutics 10-K, March 2016)
  • 29 Mar 2016 Global Blood Therapeutics plans a phase I trial for Hereditary angioedema in USA (Global Blood Therapeutics 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top